Join our growing community to challenge mainstream media bias and fix the news
GlaxoSmithKline partners CureVac to make vaccines for new Covid-19 strains

GlaxoSmithKline partners CureVac to make vaccines for new Covid-19 strains

Pharmaceutical giant GlaxoSmithKline announced that it will partner with Curevac, a German biopharmaceutical company, to develop new Covid-19 vaccines aimed at new variants of the virus. GSK said it will invest $181 million in CureVac, which is developing vaccines that use messenger RNA. GSK also said it help make up to 100 million doses of CureVac’s existing vaccine candidate this year.

KCooper
KCooper
Top in World